Our primary objective was to show non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure ( FFTF ) , by excluding a difference of 6 % after 5 years corresponding to a hazard ratio ( HR ) of 1.72 , via a 95 % CI .